Q3 2026 results
| Metric | Result | Change |
|---|---|---|
| Revenue | $1.17 billion | up 4.7% year-over-year |
| Sequencing consumables revenue | $792 million | up 6% year-over-year |
| Sequencing instruments revenue | $106 million | down 2% year-over-year |
| Operating margin | 25% | 100 basis points above guidance |
| Diluted EPS | $1.44 | up 7% year-over-year |
Guidance and outlook
- Full year 2026 revenue: $4.64 billion to $4.66 billion.
- Full year 2026 EPS: $5.40 to $5.45.
- Q4 2026 revenue: $1.22 billion to $1.24 billion.
- Q4 2026 EPS: $1.51 to $1.56.
- Q4 2026 operating margin: approximately 25%.
How management sounded
Positive (+6 on our -10 to +10 scale). Management raised full-year revenue and EPS guidance, citing strong NovaSeq X placements and healthy clinical demand, while noting that their strategic execution is delivering results. Management sounded more upbeat than on 8% of the 190 calls we cover; most companies sound positive on their own calls, so the comparison says more than the label.
Q&A summary
Clinical Consumable Growth
Asked: Analysts asked about the sustainability of clinical consumable growth and if stocking orders were involved.
Answer: Management stated clinical performance remains strong with 14% growth and they expect this to continue, noting that Q4 expectations are improving.
NovaSeq X Demand
Asked: Analysts questioned if the recent strength in NovaSeq X placements reflected a pull-forward of future demand.
Answer: Management stated they do not believe there was a pull-forward and that the demand reflects a healthy market environment and the value customers place on the Illumina ecosystem.
AI and Data Strategy
Asked: Analysts asked about the monetization of the BioInsight platform and AI data sets.
Answer: Management explained that they see a significant opportunity in generating standardized, reproducible data sets for AI models and expect BioInsight to become more visible in the P&L in 2027.
China Market
Asked: Analysts asked about the company's position in China following recent geopolitical news.
Answer: Management emphasized their commitment to the Chinese market, noting they are working closely with customers and regulators to drive innovation and maintain a path forward.
What to watch before the next call
- The company's ability to sustain high-single-digit growth in 2027 as they lap pricing headwinds.
- The evolution of the AI and predictive biology market and the contribution of the BioInsight platform to revenue.
- Ongoing geopolitical developments in China and their impact on operations.
